CD19 and leukemia: The anti-CD19 afucosylated mAb inebilizumab (MEDI-551) and the Fc-engineered (S239D/I332E) mAb tafasitamab (MOR208; XmAb5575) have been shown to enhance NK cell-mediated ADCC against B lymphoma and leukemia cell lines compared with unmodified anti-CD19 mAbs [231,232].